Results 241 to 250 of about 17,744 (296)

Contribution of two-component regulatory systems to the acute-to-chronic infection transition of <i>Pseudomonas aeruginosa</i> in cystic fibrosis. [PDF]

J Bacteriol
Flores-Vega VR, Hernández-Martínez G, Cocotl-Yañez M, Ares MA, Lincopan N, Ortiz-Navarrete V, Rosales-Reyes R.   +6 more
europepmc   +1 more source

Inhibition of EPAC1 Prevents Neuronal Death Mediated by Diesel Exhaust Particles in Ferroptotic Cell Death Conditions. [PDF]

Antioxidants (Basel)
Yan H, Zhang L, Manzano-Covarrubias AL, Gadjdjoe PS, Land A, M van der Veen CHJT, Mitchell-Garcia T, Fayyaz HA, Venema M, Åberg C, van der Hart M, Lezoualc'h F, Cheng X, Dolga AM, Schmidt M.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Phosphodiesterase in Psoriasis

British Journal of Dermatology, 1969
SUMMARY. . Phosphodiesterase activity was determined by a fluorometric method using thymidine-5′-3–0-methoxy fluorescein phosphate as a substrate, in blood serum, finger-blood, normal skin, foreskin and psoriatic skin. Higher enzyme activity was found in psoriasis both in blood-serum and finger-blood in comparison with normal controls ...
F, Zaruba, M A, Karasek, E M, Farber
openaire   +2 more sources

Lung Phosphodiesterase Isoenzymes

1993
The distinct phosphodiesterase isoenzyme activities in guinea-pig lung were identified and characterised. We demonstrate that protein kinase A catalyses the activation of lung Type V cyclic GMP phosphodiesterase. This occurs via a marked change in the Vmax for cyclic GMP hydrolysis.
Pyne, N J, Burns, F
openaire   +3 more sources

Phosphodiesterases as therapeutic targets

Urology, 2003
The advent of sildenafil (Viagra) for the treatment of erectile dysfunction has attracted widespread interests in phosphodiesterase type 5 (PDE5), the target of sildenafil, 1 and other members of the PDE superfamily. PDEs are intracellular enzymes that catalyze the hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate ...
Ching-Shwun, Lin, Zhong-Cheng, Xin, Guiting, Lin, Tom F, Lue   +3 more
openaire   +2 more sources

Phosphodiesterase 4 inhibitors

Journal of the American Academy of Dermatology, 2018
Historically, drugs available for treating atopic dermatitis (AD) have been limited to topical corticosteroids and topical calcineurin inhibitors, with systemic immunosuppressants and phototherapy reserved for severe AD. Despite their efficacy and infrequent adverse events, phobia about the use of topical steroids and calcineurin inhibitors has limited
Rema, Zebda, Amy S, Paller
openaire   +2 more sources